MX2024000118A - Anticuerpos monoclonales de adn dirigidos al virus de la influenza. - Google Patents

Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Info

Publication number
MX2024000118A
MX2024000118A MX2024000118A MX2024000118A MX2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A MX 2024000118 A MX2024000118 A MX 2024000118A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
influenza virus
antibodies targeting
targeting influenza
dna monoclonal
Prior art date
Application number
MX2024000118A
Other languages
English (en)
Inventor
David B Weiner
Jian Yan
Sarah Elliott
Ami Patel
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2024000118A publication Critical patent/MX2024000118A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe en la presente una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo sintético anti-influenza-hemaglutinina; la descripción también proporciona un método para prevenir y/o tratar la influenza en un sujeto utilizando dicha composición y método de generación.
MX2024000118A 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza. MX2024000118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17

Publications (1)

Publication Number Publication Date
MX2024000118A true MX2024000118A (es) 2024-01-22

Family

ID=60203613

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013521A MX2018013521A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2024000118A MX2024000118A (es) 2016-05-05 2018-11-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013521A MX2018013521A (es) 2016-05-05 2017-05-05 Anticuerpos monoclonales de adn dirigidos al virus de la influenza.

Country Status (11)

Country Link
US (2) US11851477B2 (es)
EP (1) EP3452504A4 (es)
JP (2) JP7506869B2 (es)
KR (3) KR20230125851A (es)
CN (2) CN118109478A (es)
AU (2) AU2017261305B2 (es)
BR (1) BR112018072708A2 (es)
CA (1) CA3023093A1 (es)
MX (2) MX2018013521A (es)
SG (2) SG10202011021XA (es)
WO (1) WO2017192946A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190116975A (ko) * 2016-11-07 2019-10-15 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
AU2022383057A1 (en) * 2021-11-05 2024-05-16 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
EP2380976A4 (en) * 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
CA2776144C (en) * 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
LT3418300T (lt) * 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
KR20150093834A (ko) * 2012-12-13 2015-08-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｄｎａ 항체 작제물 및 그 이용 방법
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
BR112017011556A2 (pt) * 2014-12-01 2018-03-06 Inovio Pharmaceuticals Inc métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
US20190091322A1 (en) 2016-03-21 2019-03-28 David B. Weiner Dna antibody constructs and method of using same

Also Published As

Publication number Publication date
SG10202011021XA (en) 2020-12-30
CN118109478A (zh) 2024-05-31
AU2017261305A8 (en) 2019-08-08
KR20190035614A (ko) 2019-04-03
BR112018072708A2 (pt) 2019-02-19
KR20230125851A (ko) 2023-08-29
US20190135899A1 (en) 2019-05-09
AU2017261305A1 (en) 2018-12-20
KR102375324B1 (ko) 2022-03-18
CN110325546A (zh) 2019-10-11
MX2018013521A (es) 2019-06-10
US11851477B2 (en) 2023-12-26
AU2017261305B2 (en) 2024-06-13
JP2022116034A (ja) 2022-08-09
WO2017192946A1 (en) 2017-11-09
EP3452504A1 (en) 2019-03-13
JP7506869B2 (ja) 2024-06-27
AU2024203297A1 (en) 2024-06-13
EP3452504A4 (en) 2020-07-29
KR20220035288A (ko) 2022-03-21
JP2019521702A (ja) 2019-08-08
WO2017192946A8 (en) 2018-12-27
CA3023093A1 (en) 2017-11-09
US20240150442A1 (en) 2024-05-09
CN110325546B (zh) 2024-03-19
SG11201809783RA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
MX2024000125A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
BR112017011326A2 (pt) anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
NZ736026A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
NZ748644A (en) Anti-cd40 antibodies and their uses
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MX2024000118A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
MX2019007924A (es) Vacunas contra la influenza.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
CR20210332A (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización